An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Public ClinicalTrials.gov record NCT00487539. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).
Study identification
- NCT ID
- NCT00487539
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 1,065 participants
Conditions and interventions
Conditions
Interventions
- Placebo Biological
- Golimumab 100 mg Biological
- Golimumab 200 mg Biological
- Golimumab 400 mg Biological
- Golimumab 50 mg Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- Sep 30, 2010
- Completion
- Sep 30, 2010
- Last update posted
- Feb 16, 2014
2007 – 2010
United States locations
- U.S. sites
- 58
- U.S. states
- 30
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Roseville | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Golden | Colorado | — | — |
| Not listed | Newark | Delaware | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | Naples | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Port Orange | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Zephyrhills | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | Arlington Heights | Illinois | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Clive | Iowa | — | — |
| Not listed | Pratt | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Monroe | Louisiana | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Pascagoula | Mississippi | — | — |
| Not listed | Tupelo | Mississippi | — | — |
| Not listed | Egg Harbor | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Asheville | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Morganton | North Carolina | — | — |
| Not listed | New Bern | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Fargo | North Dakota | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Colombus | Ohio | — | — |
| Not listed | Norman | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Limerick | Pennsylvania | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Germantown | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Sugar Land | Texas | — | — |
| Not listed | Logan | Utah | — | — |
| Not listed | Ogden | Utah | — | — |
| Not listed | Chesapeake | Virginia | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Tacoma | Washington | — | — |
| Not listed | Madison | Wisconsin | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 142 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00487539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2014 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00487539 live on ClinicalTrials.gov.